Search
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigational[L43277] Niraparib is selective towards PARP-1 and PARP-2.
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, MATE 2 Substrates with a Narrow Therapeutic IndexErtugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigationalErtugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus.
Categories: P-glycoprotein substrates, Sodium-Glucose Transporter 2 InhibitorsSynonyms: 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose, β-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-Elamipretide
go.drugbank.com/drugs/DB11981ApprovedInvestigational[A274436] Elamipretide is a synthetic tetrapeptide that selectively binds to cardiolipin, a phospholipid in the inner mitochondrial membrane. … Elamipretide is a mitochondrial cardiolipin binder being investigated for diseases involving mitochondrial dysfunction.
Categories: MATE 1 InhibitorsNirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationalNirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. … DeFi trial, where a confirmed objective response rate was observed to be 41% compared to 8% with the placebo.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesIberdomide
go.drugbank.com/drugs/DB12101Investigational[L64055] Iberdomide has shown anti-tumor activity in multiple myeloma cells resistant to lenalidomide and pomalidomide, and as a CELMoD is designed to degrade Ikaros and Aiolos more potently than immunomodulatory … accelerated approval on August 13, 2026, in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesSynonyms: (S)-3-(4-((4-(Morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, 2,6-Piperidinedione, 3-(1,3-dihydro-4-((4-(4-morpholinylmethyl)phenyl)methoxy)-1-oxo-2H-isoindol-2-yl)-, (3S)-Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigationalDefactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases … [L53198,L53208] FAK is important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key
Categories: MATE 2 Inhibitors, Cytochrome P-450 SubstratesSynonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamideDoravirine
go.drugbank.com/drugs/DB12301ApprovedInvestigationaltreatments available for the management of HIV-1 infection. … Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingFedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigationalFedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsPlazomicin
go.drugbank.com/drugs/DB12615ApprovedThe structure of plazomicin was established via appending hydroxylaminobutyric acid to [DB12604] at position 1 and 2-hydroxyethyl group at position 6' [A33942]. … Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from [DB12604].
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsZoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigational[A274938,L54748] It is indicated as a single-dose oral therapy for the treatment of uncomplicated urogenital gonorrhea. … Gonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates